Testicular germ-cell tumours (TGCTs) represent the most common solid malignancy in males aged 15 to 40 years. While relatively rare in the general population—accounting for approximately 1% of all male cancers—they are the leading cause of cancer-related death in young men. The prognosis, however, is among the best of all solid tumours, with overall cure rates exceeding 95% and approaching 99% for localized disease. This remarkable success story is built upon a foundation of multidisciplinary collaboration, effective cisplatin-based chemotherapy, sensitive tumour markers, and predictable patterns of spread.
1. Epidemiology and Risk Factors
Incidence and Demographics
The incidence of TGCTs has been rising steadily in Western countries over the past several decades, though the rate of increase appears to be slowing. There is significant geographic and ethnic variation:
- Highest rates: Northern and Western Europe (particularly Denmark, Switzerland, Norway), Australia, New Zealand, and North America.
- Lowest rates: Africa and Asia.
- Ethnicity: Caucasian men have a 4–5 times higher risk than Black or Asian men.
Age Distribution
TGCTs exhibit a distinct bimodal age distribution (though the second peak is less pronounced for non-seminoma):
- Peak 1 (Primary): Ages 25–35 (Non-seminoma peaks earlier, ~25–30; Seminoma peaks later, ~35–40).
- Peak 2 (Secondary): Ages 55–65 (Almost exclusively seminoma; spermatocytic tumour is distinct entity in older men).
- Pediatric: Pre-pubertal tumours are rare (3–5% of cases) and biologically distinct (mostly yolk sac tumours, benign teratomas).
Established Risk Factors
| Risk Factor | Relative Risk | Notes |
|---|---|---|
| Cryptorchidism (Undescended Testis) | 3–5x | Risk persists even after orchidopexy; intra-abdominal testis carries higher risk than inguinal. Orchidopexy before puberty reduces risk but does not normalize it. |
| Personal History of TGCT | 2–5% lifetime risk | Risk of contralateral tumour; highest in first 5–10 years post-diagnosis. |
| Family History | 4–6x (brother); 8–10x (father) | Suggests genetic susceptibility (polygenic inheritance); KITLG, SPRY4, BAK1 loci identified via GWAS. |
| Infertility / Subfertility | 1.5–2x | Association with poor semen parameters; shared developmental origins hypothesized. |
| Testicular Microlithiasis | Controversial | Incidental finding on US; risk significant only if combined with other risk factors (cryptorchidism, atrophy, prior TGCT). |
| HIV Infection | Slightly increased | Specifically associated with seminoma. |
| Hypospadias | 2–3x | Especially penoscrotal/perineal types. |
Key Point: The majority of men diagnosed with TGCT have no identifiable risk factors other than being a young male.
2. Anatomy and Embryology: The Origin of TGCTs
Understanding TGCTs requires understanding the gonadal ridge and primordial germ cells (PGCs).
1. Migration: PGCs originate in the yolk sac endoderm and migrate to the genital ridge (future gonad) by week 6 of gestation.
2. Malignant Transformation: It is hypothesized that failure of PGCs to differentiate correctly—or arrest in their development—leads to the formation of Germ Cell Neoplasia In Situ (GCNIS), formerly known as Carcinoma In Situ (CIS) or Intratubular Germ Cell Neoplasia (ITGCN).
3. GCNIS: This is the precursor lesion for almost all invasive TGCTs in adolescents and adults (except spermatocytic tumour and pre-pubertal tumours). GCNIS cells resemble fetal gonocytes (large nuclei, prominent nucleoli, clear cytoplasm) and express markers like PLAP, OCT3/4, and NANOG.
4. Divergence: From GCNIS, two distinct pathways emerge:
- Seminoma Pathway: Retains germ cell phenotype (resembles primordial germ cell/gonocyte).
- Non-Seminoma Pathway: Undergoes aberrant differentiation into embryonic (embryonal carcinoma) and extra-embryonic (yolk sac, choriocarcinoma) lineages, plus somatic differentiation (teratoma).
3. Histological Classification (WHO 2022 / 5th Edition)
The World Health Organization classification separates tumours derived from GCNIS (Type II) from pre-pubertal (Type I) and spermatocytic (Type III) tumours.
Major Categories
| Category | Subtypes | Key Features |
|---|---|---|
| Germ Cell Neoplasia In Situ (GCNIS) | – | Pre-invasive stage; confined to seminiferous tubules; basement membrane intact. |
| Seminoma | Classic Seminoma Seminoma with Syncytiotrophoblastic Cells |
Uniform cells; “Fried egg” appearance; lymphocytic infiltrate. |
| Non-Seminomatous Germ Cell Tumours (NSGCT) | Embryonal Carcinoma Yolk Sac Tumour Choriocarcinoma Teratoma (Post-pubertal) Mixed Germ Cell Tumour |
Heterogeneous; recapitulate embryonic/extra-embryonic/somatic differentiation. |
| Mixed Germ Cell Tumours | Any combination | Most common NSGCT presentation (e.g., Embryonal + Teratoma + Yolk Sac). Treated as Non-Seminoma. |
Clinical Rule: Any tumour containing a non-seminomatous element is staged and treated as a Non-Seminoma, regardless of the percentage of that component.
4. How Does It Look: Gross and Microscopic Pathology
This section details the visual and microscopic characteristics essential for pathological diagnosis.
4.1 Gross Appearance (Macroscopy)
Seminoma
| Feature | Seminoma (naked eye) |
|---|---|
| Size | Often 3–5 cm; can exceed 10 cm. |
| Cut surface | Uniform, lobulated, cream to grey-tan (“fish flesh”). |
| Consistency | Soft; bulges when cut. |
| Bleeding / necrosis | Little or none; marked necrosis suggests a non-seminoma component. |
| Capsule | Usually intact in early stages. |
Non-Seminoma
| Component | Naked-eye appearance |
|---|---|
| Embryonal carcinoma | Grey-tan, soft, with bleeding and map-like necrosis. |
| Yolk sac tumour | Gelatinous, mucoid or cystic; pale grey. |
| Choriocarcinoma | Dark red-black, crumbly, haemorrhagic. |
| Teratoma | Cysts with hair, sebum, mucus, cartilage or bone. |
| Overall | Mixed, variegated surface; often breaches the tunica and involves epididymis or cord. |
Burned-Out (Regressed) Germ Cell Tumour
- Appearance: Small, firm, stellate scar (fibrosis) within the testis, often with calcifications (psammoma bodies).
- Significance: Represents spontaneous regression of a primary GCT; patient presents with metastatic disease and an impalpable/normal-sized primary testis.
4.2 Microscopic Appearance (Histology)
Seminoma (Classic)
| Feature | Classic seminoma (microscope) |
|---|---|
| Architecture | Sheets and nests divided by thin fibrous septa. |
| Stroma | Many lymphocytes; granulomas are common. |
| Cells | Large, polygonal, with clear borders and glycogen-rich clear cytoplasm. |
| Nuclei | Large, central, with prominent nucleoli; frequent mitoses. |
| hCG-producing giant cells | In about 15–20%; do not change the diagnosis to non-seminoma. |
Embryonal Carcinoma (The “Stem Cell” of NSGCT)
| Feature | Embryonal carcinoma |
|---|---|
| Architecture | Solid sheets, glands, tubules or papillae. |
| Cells and nuclei | Large, pleomorphic, overlapping nuclei with several nucleoli; scant cytoplasm. |
| Mitoses | Numerous, often abnormal. |
| Necrosis | Extensive map-like (geographic) necrosis. |
Yolk Sac Tumour (Endodermal Sinus Tumour)
| Feature | Yolk sac tumour |
|---|---|
| Architecture | Varied: microcystic, solid, papillary, glandular, hepatoid. |
| Classic sign | Schiller-Duval bodies (glomerulus-like structures), seen in about 50%. |
| Cells | Cuboidal or flat with pale cytoplasm; PAS-positive hyaline globules. |
| Markers | AFP, glypican-3 and SALL4 positive. |
Choriocarcinoma
| Feature | Choriocarcinoma |
|---|---|
| Pattern | Two intermixed cell types in a bloody background, without villi. |
| Cytotrophoblast | Single-nucleus cells with clear cytoplasm and sharp borders. |
| Syncytiotrophoblast | Multinucleated giant cells with dark cytoplasm. |
| Markers | hCG strongly positive; AFP negative. |
Teratoma (Post-Pubertal / Type II)
| Aspect | Post-pubertal teratoma |
|---|---|
| Definition | Tissues from all three germ layers (skin, nerve, cartilage, bone, gut or airway lining). |
| Maturity | Mature (fully formed tissues) or immature (embryonic-type tissue). |
| Behaviour | Malignant: can spread, because it arises from GCNIS; unlike pre-pubertal teratoma, which is benign. |
| Treatment point | Resistant to chemotherapy; residual teratoma must be removed surgically. |
4.3 Immunohistochemistry (IHC) Panel: The Diagnostic Workhorse
| Marker | Seminoma | Embryonal Carcinoma | Yolk Sac Tumour | Choriocarcinoma | Teratoma (Somatic) | GCNIS |
|---|---|---|---|---|---|---|
| PLAP | + (Strong, membranous) | -/+ | – | – | – | + |
| OCT3/4 | + (Nuclear) | + (Nuclear) | – | – (Cytotrophoblast +) | – | + |
| SALL4 | + (Nuclear) | + (Nuclear) | + (Nuclear) | + (Cytotrophoblast) | Variable | + |
| CD30 | – | + (Membranous/Golgi) | – | – | – | – |
| CD117 (c-KIT) | + (Membranous) | – | – | – | – | + |
| D2-40 (Podoplanin) | + (Membranous) | – | – | – | – | + |
| AFP | – | – (Focal rare) | + (Cytoplasmic) | – | Focal (Gut epithel.) | – |
| hCG | – (STGCs only) | – | – | + (Syncytio.) | Focal (Trophoblast) | – |
| Glypican-3 | – | – | + | – | – | – |
| Keratin (AE1/AE3) | + | + | + | + | + | + |
| SOX17 | + (Nuclear) | – | – | – | – | + |
| GATA3 | – | – | – | + | – | – |
Diagnostic Pearls:
- Seminoma vs Embryonal: CD30 (+) in Embryonal; CD117/D2-40/OCT3/4 (+) in Seminoma.
- Yolk Sac vs Teratoma (Glandular): Glypican-3 / SALL4 (+) in YST; usually negative in benign glands of teratoma.
- Seminoma vs Spermatocytic Tumour: Spermatocytic tumour is OCT3/4 negative, CD117 negative, D2-40 negative, c-KIT negative, but SALL4 positive. It occurs in older men (>50) and has no metastatic potential.
5. Symptoms and Clinical Presentation
The clinical presentation of TGCT is often subtle. High awareness is critical because delays in diagnosis (patient or physician delay) are the most common cause of advanced stage at presentation.
5.1 Primary Testicular Symptoms (Local)
| Symptom / Sign | Frequency | Description & Clinical Nuance |
|---|---|---|
| Painless Scrotal Mass / Swelling | ~80–90% | The hallmark presentation. Usually firm, non-tender, intra-testicular. May be discovered incidentally by patient or partner. |
| Testicular Pain / Discomfort | ~10–20% | Dull ache, heaviness, or dragging sensation in scrotum, groin, or lower abdomen. Acute severe pain is rare but can indicate haemorrhage, infarction, or torsion of the tumour. Pain does not rule out cancer. |
| Testicular Atrophy / Shrinkage | Occasional | Tumour replaces parenchyma; contralateral testis may be small due to subfertility/GCNIS. |
| Gynecomastia | ~5–10% (Higher in NSGCT/Choriocarcinoma) | Tender breast enlargement. Caused by hCG (LH-like activity stimulating Leydig cells → oestrogen) or altered androgen/oestrogen ratio. Bilateral usually; unilateral possible. |
| Hydrocele | ~10% | Reactive fluid around tumour. Crucial: A new hydrocele in an adult must be investigated with ultrasound; do not assume benign. Tumour may be masked by fluid. |
5.2 Symptoms of Metastatic Disease (Systemic)
TGCTs follow a predictable lymphatic drainage pattern (retroperitoneal nodes) followed by haematogenous spread.
| Site of Spread | Symptoms / Signs | Subtype Association |
|---|---|---|
| Retroperitoneal Lymph Nodes (RPLN) | Often asymptomatic. • Back/flank pain (mass effect on psoas/ureter). • Early satiety, nausea (mass effect on bowel/stomach). • Lower limb edema (IVC compression). • Varicocele (Left > Right; IVC/renal vein obstruction). |
Both (Primary landing zone) |
| Lungs (Pulmonary Mets) | • Asymptomatic (incidental on CXR/CT). • Cough, dyspnoea, haemoptysis (large volume). • Pleural effusion. |
Both (Common 2nd site) |
| Liver / Viscera | • RUQ pain, hepatomegaly, jaundice (late). | Non-seminoma (Late) |
| Brain | • Headaches, seizures, focal deficits, personality changes. | Choriocarcinoma (High propensity); Embryonal Carcinoma. |
| Bone | • Bone pain, pathological fracture. | Late, all subtypes. |
| Mediastinum / Neck Nodes | • Supraclavicular mass (Virchow’s node / Troisier sign). • Cough, stridor (mediastinal mass). |
Non-seminoma (especially if primary mediastinal GCT). |
5.3 Paraneoplastic Syndromes
Rare but clinically significant:
- Limbic Encephalitis: Associated with Ma2 antibodies (anti-Ma2). Presents with memory loss, seizures, hypothalamic dysfunction (hyperphagia, sleep disorders). Strongly linked to TGCT (often seminoma).
- Dermatomyositis / Paraneoplastic Pemphigus: Rare associations.
- Hyperthyroidism: Due to extremely high hCG (thyroid-stimulating activity) in choriocarcinoma.
5.4 The “Burned-Out” Primary
- Presentation: Patient presents with metastatic disease (large retroperitoneal mass, lung mets) but normal testicular exam and normal ultrasound (or only a small calcific scar).
- Mechanism: Primary tumour outgrows blood supply, undergoes infarction/fibrosis, and regresses, leaving metastatic deposits viable.
- Management: Treat as metastatic TGCT based on histology of metastatic biopsy (or serum markers). Orchiectomy still recommended to remove GCNIS/scar.
6. Diagnostic Workup
6.1 Scrotal Ultrasound (First-Line Imaging)
| Aspect | Details |
|---|---|
| Accuracy | Over 95% sensitive for masses inside the testis. |
| Key distinction | Masses inside the testis are cancer until proven otherwise; masses outside are usually benign. |
| Seminoma | Uniform, dark (hypoechoic), well-defined, with blood flow. |
| Non-seminoma | Mixed echoes, calcifications, cysts, irregular edges. |
| Microcalcifications | Non-specific; matter only with other risk factors. |
6.2 Serum Tumour Markers (STM) – Mandatory Pre-Orchiectomy
Markers are essential for diagnosis, staging, risk stratification, and monitoring. Must be drawn before orchiectomy (half-lives are short; surgery alters kinetics).
| Marker | Half-Life | Produced By | Clinical Utility |
|---|---|---|---|
| AFP (Alpha-Fetoprotein) | 5–7 days | Yolk Sac Tumour, Embryonal Carcinoma | Never elevated in pure Seminoma. If elevated → Non-Seminoma. |
| hCG (Beta-hCG) | 24–36 hours | Syncytiotrophoblast (Choriocarcinoma, STGCs in Seminoma/Embryonal) | Elevated in ~15% Seminomas (STGCs), ~40-60% NSGCT. Very high = Choriocarcinoma. |
| LDH (Lactate Dehydrogenase) | < 24 hours | Non-specific (tumour bulk, proliferation, necrosis) | Prognostic factor (IGCCCG). Less specific; elevated in many conditions. |
| PLAP | – | Seminoma, GCNIS | Historical; rarely used now (replaced by IHC). |
Critical Interpretation Rules:
1. Normal markers ≠ No Cancer. 20-30% of NSGCT and 85% of Seminoma have normal markers.
2. AFP Elevation = Non-Seminoma. No exceptions. Treat as NSGMA even if histology looks like seminoma (sampling error).
3. Marker Decline Kinetics: Post-orchiectomy, markers must decline with expected half-life. Failure to normalize = Residual disease.
6.3 Staging Imaging
- CT Abdomen/Pelvis (Contrast): Gold standard for retroperitoneal lymph nodes (RPLN). Size criteria: Short axis > 10 mm = suspicious.
- Chest Imaging: CT Chest preferred (detects small nodules <1cm) vs CXR.
- Brain MRI: Indicated only if: Neurological symptoms, Choriocarcinoma histology, Very high hCG (>10,000 IU/L), Multiple lung mets.
- Bone Scan / PET-CT: Not routine for initial staging. FDG-PET/CT has a specific role in Seminoma post-chemotherapy (residual mass >3cm) to differentiate viable tumour vs fibrosis. Not recommended for NSGCT (teratoma is FDG-avid false positive; viable tumour may be false negative).
6.4 Inguinal Radical Orchiectomy: Diagnosis & Primary Treatment
| Aspect | Details |
|---|---|
| Approach | Through the groin, not the scrotum; cord tied high at the internal ring. |
| Prosthesis | Silicone implant offered at surgery or later. |
| Sperm banking | Offered before surgery as standard care. |
| Pathology | Confirms subtype and mix, vessel and rete testis invasion, and pT stage. |
7. Staging Systems
Two systems are used concurrently: TNM (AJCC 8th Ed / UICC) for anatomical extent and IGCCCG (International Germ Cell Cancer Collaborative Group) for metastatic risk stratification.
7.1 TNM Staging (Primary Tumour – pT)
| pT Category | Definition |
|---|---|
| pTis | GCNIS (Intratubular neoplasia) |
| pT1 | Tumour limited to testis/epididymis WITHOUT LVI; may invade tunica albuginea but NOT tunica vaginalis. |
| pT2 | Tumour limited to testis/epididymis WITH LVI OR tumour extending through tunica albuginea into tunica vaginalis. |
| pT3 | Tumour invades spermatic cord (with or without LVI). |
| pT4 | Tumour invades scrotum (skin, dartos, scrotal wall). |
Note: Scrotal violation (biopsy, previous surgery, pT4) upstages to at least Stage IIB/III or alters lymphatic drainage (inguinal nodes become relevant).
7.2 Stage Grouping (Simplified)
| Stage | TNM | Clinical Scenario |
|---|---|---|
| Stage 0 | pTis, N0, M0, S0 | GCNIS only. |
| Stage I | pT1-4, N0, M0, SX | Tumour confined to testis (no nodal/metastatic spread). Markers may be elevated (SX) but must normalize post-op. |
| Stage IS | Any pT, N0, M0, S1-3 | Markers fail to normalize or rise post-orchiectomy = Occult metastatic disease. Treated as metastatic. |
| Stage II | Any pT, N1-3, M0, S0-1 | Retroperitoneal nodal involvement only. Subdivided by node size/number (IIA, IIB, IIC). |
| Stage III | Any pT, Any N, M1, Any S | Distant metastasis (Lung, Liver, Brain, Bone, Non-regional nodes). Subdivided by IGCCCG risk. |
7.3 IGCCCG Prognostic Classification (For Metastatic Disease – Stage IIB/IIC/III)
Used to assign Good, Intermediate, or Poor Risk → dictates chemotherapy intensity (3 vs 4 cycles BEP).
| Risk Group | Seminoma | Non-Seminoma |
|---|---|---|
| Good | Any primary site. No non-pulmonary visceral mets. Normal AFP. (hCG & LDH any level) |
Testis/Retroperitoneal primary. No non-pulmonary visceral mets. Low Markers: AFP < 1000, hCG < 5000, LDH < 1.5x ULN. |
| Intermediate | Non-pulmonary visceral mets present (Liver, Bone, Brain). (Markers any level). |
Testis/Retroperitoneal primary. No non-pulmonary visceral mets. Intermediate Markers: AFP 1000–10,000 OR hCG 5,000–50,000 OR LDH 1.5–10x ULN. |
| Poor | Does not exist for Seminoma. (All metastatic seminoma = Good or Intermediate). | Mediastinal Primary OR Non-pulmonary visceral mets OR High Markers: AFP > 10,000 OR hCG > 50,000 OR LDH > 10x ULN. |
8. Management by Stage and Subtype
Management is highly protocol-driven (NCCN, ESMO, EAU guidelines). Multidisciplinary Team (MDT) discussion is mandatory.
8.1 Stage I Disease (Localized)
Stage I Seminoma
| Option | Details | Relapse risk | Downsides |
|---|---|---|---|
| Surveillance (preferred) | Markers, examination and CT: every 3–6 months for years 1–2, then less often to year 5. | About 15–20%, mostly in abdominal nodes; nearly all cured with chemotherapy. | Repeated scans and visits. |
| Carboplatin (one dose, AUC 7) | Single adjuvant cycle. | About 3–5%. | Small long-term risks. |
| Radiotherapy | Para-aortic or “dog-leg” field; historical standard. | Low. | Heart disease, second cancers, fertility effects; no longer preferred. |
Stage I Non-Seminoma
Risk stratification based on Lymphovascular Invasion (LVI) on pathology.
| Risk Group | LVI Status | Relapse Risk (Surveillance) | Options |
|---|---|---|---|
| Low Risk (pT1) | Absent | ~15% | Surveillance (Preferred). Intense schedule (Months 1-2: q2mo; Yr1: q2mo; Yr2: q3mo; Yr3-5: q6mo; Yr5+: q12mo). CT Abd/Pelvis q3-6mo x 3yrs. |
| High Risk (pT2-4) | Present | ~50% | 1. Surveillance (Acceptable if compliant, high-volume center). 2. Adjuvant Chemotherapy: 1 Cycle BEP (Bleomycin, Etoposide, Cisplatin). Reduces relapse to <3%. Standard in many centers for high risk. 3. RPLND (Retroperitoneal Lymph Node Dissection): Surgical staging + treatment. Nerve-sparing preserves antegrade ejaculation. Morbidity higher than chemo. |
Stage IS (Marker Positive Post-Orchiectomy): Treat as Metastatic Disease (Good Risk). Chemotherapy (3 cycles BEP or 4 cycles EP). Do not give radiotherapy or RPLND initially.
8.2 Stage II Disease (Regional Nodal)
Stage IIA/IIB Seminoma (Nodes < 3-5 cm)
- Primary Chemotherapy: 3 cycles BEP or 4 cycles EP (Standard). Preferred over Radiotherapy due to lower late toxicity.
- Radiotherapy (Extended Field): Option for IIA (<3cm) if chemo contraindicated. Higher relapse in pelvis/mediastinum later.
- Surveillance post-Chemo: Residual mass <3cm → Observe. Residual mass >3cm → PET-CT at 3 months post-chemo. PET+ → Biopsy/Resection. PET- → Observe.
Stage IIC/III Seminoma (Bulky Nodes >5cm or Visceral Mets)
- Primary Chemotherapy: 4 cycles EP (Standard) or 3-4 cycles BEP.
- Radiotherapy: Not used for bulky disease.
- Residual Mass Management: Same as above (PET-CT guided).
Stage II Non-Seminoma
| Situation | Treatment | Follow-on |
|---|---|---|
| Low volume (IIA/IIB), normal markers | Nerve-sparing RPLND, or chemotherapy (3 BEP or 4 EP) if surgery unsuitable. | After RPLND: surveillance if no nodes or teratoma only; 2 cycles of chemotherapy may be offered for viable cancer. |
| High volume (IIC) or raised markers | 3 BEP or 4 EP (good risk). | Surgery for residual masses over 1 cm, because teratoma resists chemotherapy. |
8.3 Stage III Disease (Metastatic / Advanced)
Good Risk (Both Subtypes)
- Standard: 3 cycles BEP (Bleomycin, Etoposide, Cisplatin x 3 weeks).
- Alternative (Seminoma / Lung toxicity risk): 4 cycles EP (Etoposide + Cisplatin). Equivalent efficacy, less pulmonary toxicity.
- Cure Rate: >90%.
Intermediate Risk (Non-Seminoma only)
- Standard: 4 cycles BEP.
- Dose-Dense / High-Dose Strategies: Investigational (e.g., TIP, VIP, High-dose chemo + stem cell rescue) – not standard first-line.
Poor Risk (Non-Seminoma only)
- Standard: 4 cycles BEP.
- Alternative: 4 cycles VIP (Etoposide, Ifosfamide, Cisplatin) – avoids Bleomycin (pulmonary toxicity), better for baseline lung issues.
- High-Dose First Line: Not proven superior to standard BEP in RCTs (e.g., GETUG 13, SWOG S9512). Reserved for clinical trials or relapse.
- Cure Rate: 50–70%.
8.4 Post-Chemotherapy Residual Mass Resection (PC-RPLND / Metastasectomy)
| Aspect | Details |
|---|---|
| Indication | Residual mass over 1 cm (non-seminoma) or PET-positive mass over 3 cm (seminoma) after chemotherapy, with normal markers. |
| Necrosis or scar (about 50%) | No further treatment. |
| Teratoma (35–40%) | Surgery alone is curative. |
| Viable cancer (10–15%) | Usually 2 further cycles of chemotherapy (e.g. EP or TIP). |
| Complexity | May require removal of kidney, vena cava or aorta segments; high-volume centres only. |
8.5 Relapsed / Refractory Disease
- Salvage Chemotherapy: TIP (Paclitaxel, Ifosfamide, Cisplatin) or VeIP (Vinblastine, Ifosfamide, Cisplatin) are standard 2nd line.
- High-Dose Chemotherapy (HDCT) + Autologous Stem Cell Rescue (ASCR): Standard for first relapse after cisplatin-based chemo (especially if early relapse <2yrs, or poor risk features). TICE or Carboplatin/Etoposide conditioning.
- Third-Line+: Gemcitabine/Oxaliplatin (GEMOX), Paclitaxel/Gemcitabine, Immunotherapy (Pembrolizumab – active in refractory GCT), Clinical Trials.
- Late Relapse (>2 years post-chemo): Often Teratoma or Somatic-type Malignancy (Sarcoma, Carcinoma). Surgery is primary treatment. Chemo less effective.
9. Special Clinical Scenarios
9.1 Bilateral Testicular Cancer
- Synchronous (Simultaneous): ~1-2%. Bilateral orchiectomy → Testosterone replacement mandatory. Sperm banking before first surgery critical.
- Metachronous (Sequential): ~2-3% cumulative risk at 15-20 years. Contralateral surveillance (US, exam) or biopsy for GCNIS at time of first orchiectomy (controversial/varies by guideline). If GCNIS found: Low-dose Radiotherapy (20 Gy) eradicates GCNIS preserving Leydig function (mostly).
9.2 Extragonadal Germ Cell Tumours (EGGCT)
- Sites: Anterior Mediastinum (most common), Retroperitoneum, Pineal/Suprasellar (Brain).
- Biology: Arise from mis-migrated PGCs. No testicular primary found.
- Mediastinal Non-Seminoma: Automatically “Poor Risk” (IGCCCG) regardless of markers. High association with Klinefelter Syndrome (47,XXY).
- Treatment: Same systemic chemo protocols. Resection of residual mediastinal mass high morbidity (thoracotomy/sternotomy).
9.3 Testicular Cancer in Special Populations
- Adolescents (13-18 yrs): Biology similar to adults. Treatment protocols identical. Fertility preservation (sperm banking) paramount. Psychosocial support critical.
- Older Adults (>60 yrs): Higher comorbidity, reduced renal function, neuropathy risk. Carboplatin often substituted for Cisplatin (less nephro/neuro/ototoxicity) in adjuvant setting. BEP tolerated poorly; EP or Carbo/Etoposide preferred.
- HIV+ Patients: Higher incidence of Seminoma. Standard chemo (BEP/EP) feasible with G-CSF support and ART management. Drug interactions (CYP3A4) with protease inhibitors/NNRTIs require dose adjustments.
10. Long-Term Survivorship and Late Effects
With cure rates >95%, the population of survivors is large (approx. 250,000+ in US alone). Long-term follow-up (LTFU) is a distinct medical necessity.
10.1 Second Malignant Neoplasms (SMN)
- Risk: 2-3x general population risk. Cumulative incidence ~15-20% at 25-30 years.
- Types: Solid tumours in radiation fields (GI tract, lung, bladder, contralateral testis) + Chemotherapy-related (AML/MDS – etoposide/alkylators).
- Screening: Colonoscopy earlier (age 40 or 10yrs post-RT), Lung CT (if smoked/RT), Skin exams.
10.2 Cardiovascular Disease (CVD)
- Leading cause of non-cancer death in survivors.
- Mechanisms: Cisplatin (endothelial dysfunction, Raynaud’s, dyslipidemia, metabolic syndrome), Radiation (coronary artery disease, valvulopathy), Bleomycin (pulmonary HTN).
- Metabolic Syndrome: High prevalence (obesity, hypertension, insulin resistance, dyslipidemia).
- Management: Aggressive risk factor modification (Statins, ACEi, lifestyle). Echocardiogram surveillance if anthracyclines/RT used (rare in GCT but possible in salvage).
10.3 Hypogonadism / Testosterone Deficiency
- Prevalence: 20-40% long-term.
- Causes: Bilateral orchiectomy; Cisplatin toxicity to Leydig cells; Radiation scatter; LH feedback disruption.
- Monitoring: Annual Total Testosterone (morning), LH, FSH.
- Treatment: Testosterone Replacement Therapy (TRT) if symptomatic + low levels. Monitor haematocrit, PSA.
10.4 Fertility and Sexual Function
- Fertility: ~50-70% recover spermatogenesis post-chemo (often takes 2-5 years). Cryopreservation pre-treatment is gold standard. p53 status predicts recovery.
- Ejaculatory Dysfunction: Retrograde ejaculation / Anejaculation post-RPLND. Nerve-sparing RPLND preserves emission in >90%. Penile vibratory stimulation / Electroejaculation / Sperm retrieval (TESE/MESA) for IVF/ICSI.
- Erectile Dysfunction: Psychogenic, vascular (CVD), neurogenic (RPLND), hormonal. PDE5 inhibitors effective.
10.5 Pulmonary Toxicity (Bleomycin)
- Risk: Cumulative dose >300-400 units; Age >40; Smoking; Pre-existing lung disease; High FiO2 (perioperative).
- Manifestation: Pulmonary fibrosis, restrictive lung disease. Irreversible.
- Precaution: Lifelong avoidance of high FiO2 (>50%) during anaesthesia unless absolutely necessary. Medic alert bracelet recommended.
10.6 Neuropathy & Nephrotoxicity (Cisplatin)
- Neuropathy: Sensory (stocking-glove), dose-limiting. Can be permanent. Ototoxicity (high-frequency hearing loss, tinnitus) – irreversible.
- Nephrotoxicity: Reduced GFR, Magnesium wasting (hypomagnesemia), distal RTA. Monitor electrolytes, renal function long-term.
10.7 Psychosocial Health
- Fear of recurrence (Scanxiety).
- Body image (orchiectomy, scars).
- Financial toxicity.
- Relationship/Intimacy issues.
- Recommendation: Routine distress screening; referral to psycho-oncology, survivorship clinics.
11. Follow-Up Schedule (Survivorship Care Plan)
Frequency depends on Stage, Treatment Received, and Time since Treatment.
| Timeframe | History & Physical | Tumour Markers (AFP, hCG, LDH) | Imaging | Labs / Other |
|---|---|---|---|---|
| Years 1-2 | Every 2-3 months | Every 2-3 months | CT Abd/Pelvis: q3-6 mo. Chest CT/XR: q3-6 mo. |
CBC, CMP, Mg, TSH, Testosterone, Lipids, Fasting Glucose/HbA1c annually. |
| Years 3-5 | Every 4-6 months | Every 4-6 months | CT Abd/Pelvis: q6-12 mo. Chest XR/CT: q6-12 mo. |
Cardiovascular risk assessment. Audiology baseline. |
| Years 5-10 | Every 6-12 months | Every 6-12 months | CT Abd/Pelvis: Annually (or q2yrs if low risk). Chest XR: Annually. |
SMN Screening (Colonoscopy, Lung CT if indicated). |
| Year 10+ | Annually | Annually | Consider stopping imaging if low risk (Stage I seminoma surveillance). Individualize. | Transition to Primary Care / Survivorship Clinic with shared care plan. |
Note: Seminoma follow-up extends longer (relapses can occur >10 years). Non-seminoma relapses rare >5 years (except late relapse teratoma/somatic malignancy).
12. Summary: Key Takeaways for the Patient
- Testicular cancer is highly curable. Even if spread has occurred, the vast majority of men are cured.
- Know your body. Monthly testicular self-exam (TSE) after a warm shower is the best way to find a lump early.
- Don’t ignore a lump. Painless does not mean benign. See a doctor immediately.
- Bank sperm before treatment. Chemotherapy, radiation, and surgery can affect fertility. Sperm banking is safe, easy, and preserves future options.
- Ask for a Specialist. Treatment at a high-volume center with a multidisciplinary team (Urologist, Medical Oncologist, Radiation Oncologist, Pathologist, Radiologist) improves outcomes.
- Follow-up is for life. The treatment saves your life, but it has long-term consequences (heart, lungs, hormones, second cancers). A Survivorship Care Plan is your roadmap for staying healthy decades later.
- You are not alone. Support groups and survivorship networks provide invaluable peer support.
13. Resources and References (Harvard Style)
- Albers, P., Albrecht, W., Algaba, F., Bokemeyer, C., Cohn-Cedermark, G., Fizazi, K., … & Lam, T. (2022) EAU Guidelines on Testicular Cancer. European Association of Urology. Available at: https://uroweb.org/guideline/testicular-cancer/ (Accessed: October 2026).
- National Comprehensive Cancer Network (2024) NCCN Clinical Practice Guidelines in Oncology: Testicular Cancer. Version 2.2024. Plymouth Meeting, PA: NCCN. Available at: https://www.nccn.org/professionals/physician_gls/pdf/testicular.pdf (Accessed: October 2026).
- Motzer, R.J., Agarwal, N., Beard, C., Bolger, G.B., Boston, B., Carducci, M.A., … & Shead, D.A. (2024) ‘Testicular Cancer, Version 2.2024’, Journal of the National Comprehensive Cancer Network, 22(4), pp. 298-331.
- International Germ Cell Cancer Collaborative Group (1997) ‘International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers’, Journal of Clinical Oncology, 15(2), pp. 594-603.
- Gilligan, T.D., Linch, M., Knez-Perez, M., Pal, S.K., Powles, T., Rieger-Christ, K.M., … & Einhorn, L.H. (2023) ‘Testicular Cancer: ASCO Guideline Update’, Journal of Clinical Oncology, 41(17), pp. 3028-3051.
- WHO Classification of Tumours Editorial Board (2022) Urinary and Male Genital Tumours. 5th edn. Lyon: International Agency for Research on Cancer (WHO Classification of Tumours Series).
- Ulbright, T.M. (2023) ‘Germ cell neoplasms of the testis’, American Journal of Surgical Pathology, 47(1), pp. e1-e27.
- Travis, L.B., Beard, C., Allan, J.M., Dahl, A.A., Feldman, D.R., Oldenburg, J., … & Oeffinger, K.C. (2010) ‘Testicular cancer survivorship: research strategies and recommendations’, Journal of the National Cancer Institute, 102(16), pp. 1114-1130.
- Huddart, R.A., Norman, A., Shahidi, M., Horwich, A., Shipley, J., Peckham, M.J., … & Dearnaley, D.P. (2003) ‘Cardiovascular disease as a long-term complication of treatment for testicular cancer’, Journal of Clinical Oncology, 21(8), pp. 1513-1523.
- Van den Belt-Dusebout, A.W., Nuver, J., de Wit, R., Gietema, J.A., ten Bokkel Huinink, D., van der Graaf, W.T., … & Schaapveld, M. (2007) ‘Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer’, Journal of Clinical Oncology, 25(30), pp. 4370-4378.
- Fung, C., Dinh, T., Ardeshir-Rouhanifard, S., Einhorn, L.H. and Abonour, R. (2017) ‘Salvage treatment for relapsed testicular germ cell tumors’, Current Treatment Options in Oncology, 18(11), p. 67.
- Lorch, A., Beyer, J., Bascoul-Mollevi, C., Gill, D., Jewett, M., Oing, C., … & Hartmann, J.T. (2019) ‘Long-term outcomes of patients with relapsed or refractory germ cell tumours treated with pembrolizumab in the KEYNOTE-057 trial’, Annals of Oncology, 30(8), pp. 1341-1348.
- Winter, C. and Albers, P. (2020) ‘Testicular germ cell tumours: pathogenesis, diagnosis and treatment’, Nature Reviews Disease Primers, 6(1), pp. 1-20.
- American Cancer Society (2024) Cancer Facts & Figures 2024. Atlanta: American Cancer Society.
- Cancer Research UK (2023) Testicular cancer statistics. Available at: https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/testicular-cancer (Accessed: October 2026).